Alpine Woods Capital Investors’s Myriad Genetics MYGN Stock Holding History

Alpine Woods Capital Investors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7,900	Closed	-$215K	–	273
2019 Q4	$215K	Sell	7,900 -700	-8%	-$19.3K	0.04%	241
2019 Q3	$246K	Sell	8,600 -200	-2%	-$5.83K	0.05%	230
2019 Q2	$244K	Sell	8,800 -14,000	-61%	-$395K	0.05%	247
2019 Q1	$757K	Buy	22,800 +7,790	+52%	+$237K	0.16%	129
2018 Q4	$436K	Hold	15,010	–	–	0.1%	180
2018 Q3	$690K	Buy	+15,010	New	+$667K	0.14%	127
2015 Q4	–	Sell	-10,000	Closed	-$375K	–	471
2015 Q3	$375K	Hold	10,000	–	–	0.02%	358
2015 Q2	$340K	Sell	10,000 -10,000	-50%	-$340K	0.02%	368
2015 Q1	$708K	Hold	20,000	–	–	0.04%	287
2014 Q4	$681K	Hold	20,000	–	–	0.03%	286
2014 Q3	$771K	Sell	20,000 -10	-0%	-$373	0.04%	274
2014 Q2	$779	Hold	20,010	–	–	0.02%	257
2014 Q1	$684K	Sell	20,010 -4,990	-20%	-$155K	0.04%	257
2013 Q4	$524K	Hold	25,000	–	–	0.03%	275
2013 Q3	$588K	Hold	25,000	–	–	0.04%	250
2013 Q2	$672K	Buy	+25,000	New	+$725K	0.04%	224

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alpine Woods Capital Investors's MYGN Position: Q1 2020 in Review

Alpine Woods Capital Investors sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 7,900 shares — an estimated $215K sold.

Alpine Woods Capital Investors first reported a position in MYGN in Q2 2013 and held it in 16 quarters. The position peaked at $771K in Q3 2014. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

Alpine Woods Capital Investors reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
Alpine Woods Capital Investors sold 7,900 Myriad Genetics shares in Q1 2020, an estimated $215K.
Alpine Woods Capital Investors first reported a position in Myriad Genetics in Q2 2013 and held it in 16 quarters.
Alpine Woods Capital Investors's Myriad Genetics position peaked at $771K in Q3 2014.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Alpine Woods Capital Investors's 13F filing for Q1 2020, filed 4 May 2020.